← All trials
NCT06793137
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 22, 2024
- Primary completion
- Oct 31, 2025
- Completion date
- Apr 30, 2026
- First posted
- Jan 27, 2025
- Last posted
- Jan 29, 2025
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hospital A.C. CamargoLead sponsor
- Hospital A.C. CamargoOfficial
- Hospital A.C. CamargoSponsor investigator
- Conselho Nacional de Desenvolvimento Científico e TecnológicoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.